

			Intervention						
			Explore alternatives (e.g., monoclonals) ¹	Better understand burden/epidemiology/transmission	Incentivise multi-pathogen / combination vaccines	Pre-clinical research (e.g., antigen discovery & selection, animal models)	Improve translatability and/or support more first-in-human trials	Accelerate clinical development	Drive coverage and equity
Pathogen clusters	Increase uptake	<i>H. influenzae</i>		✓					✓
		<i>S. pneumoniae</i>				✓			✓
		<i>S. Typhi</i>			✓				✓
	Bring to market	<i>E. coli</i> (enteric)		✓	✓	✓		✓	
		Non-typhoidal <i>Salmonella</i>		✓	✓			✓	
		<i>Shigella</i> spp.			✓			✓	
	Advance early R&D	<i>M. tuberculosis</i> ²				✓	✓		
		<i>N. gonorrhoeae</i>			✓	✓	✓		
		<i>E. coli</i> (urinary)	✓	✓		✓			
		<i>P. aeruginosa</i>	✓	✓		✓			
		<i>S. aureus</i>	✓	✓		✓	✓		
	Collect data, explore alternatives	<i>S. Paratyphi</i>			✓			✓	
		<i>Campylobacter</i> spp.	✓	✓	✓				
		<i>H. pylori</i>	✓	✓		✓			
		<i>K. pneumoniae</i>	✓	✓		✓			
		<i>A. baumannii</i>	✓	✓					
		<i>E. faecium</i>	✓	✓					
		<i>Enterobacteriaceae</i>	✓	✓					

 Primary Recommendation
  Secondary Recommendation

1) Requires better understanding of disease biology (i.e., investments in pre-clinical research). Recommendations have focus on vaccine dev; 2) BCG vaccine is excluded here. Focus on broadly efficacious TB vaccine.